Table 1.
Triglycerides
|
HDL-C
|
Total cholesterolb
|
LDL-C
|
|||||
---|---|---|---|---|---|---|---|---|
Slope | P-value | Slope | P-value | Slope | P-value | Slope | P-value | |
All studies (N=40) | 0.488 | 0.005 | 0.085 | 0.822 | 1.030 | <0.001 | 0.624 | <0.001 |
Population (N=36)c | ||||||||
Primary prevention (N=11) | 1.031 | 0.010 | 2.251 | 0.223 | 1.232 | 0.044 | 0.932 | 0.002 |
Secondary prevention (N=25) | 0.373 | 0.114 | −0.288 | 0.487 | 1.264 | <0.001 | 0.507 | <0.001 |
HDL-C level (N=40) | ||||||||
Low (N=20) | 0.605 | 0.013 | 0.127 | 0.773 | 1.294 | <0.001 | 0.539 | <0.001 |
High (N=20) | 0.624 | 0.018 | 0.719 | 0.367 | 0.602 | 0.041 | 0.776 | <0.001 |
LDL-C level (N=40) | ||||||||
Low (N=20) | 0.765 | 0.010 | 0.252 | 0.625 | 0.952 | <0.001 | 0.585 | <0.001 |
High (N=20) | 0.352 | 0.136 | −0.460 | 0.497 | 1.392 | <0.001 | 0.888 | <0.001 |
Total cholesterol level (n=38)b | ||||||||
Low (N=19) | 0.765 | 0.005 | −1.575 | 0.023 | 0.844 | <0.001 | 0.594 | <0.001 |
High (N=19) | 0.456 | 0.107 | −0.455 | 0.502 | 1.475 | <0.001 | 1.026 | <0.001 |
Notes:
Bold font indicates statistical significance at P<0.05
JUPITER and AIM-HIGH, which did not report total cholesterol, were omitted from analyses of total cholesterol
the analyses omitted the four trials with mixed primary and secondary populations.
Abbreviations: AIM-HIGH, Atherothrombosis Intervention in Metabolic syndrome with low HDL/High triglycerides: Impact on Global Health outcomes; HDL-C, high-density lipoprotein cholesterol; JUPITER, Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin; LDL-C, low-density lipoprotein cholesterol.